Urolithin a inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages

Bowen Zheng,Yuying Wang,Baian Zhou,Fengyuan Qian,Diya Liu,Danrong Ye,Xiqian Zhou,Lin Fang
DOI: https://doi.org/10.1016/j.jare.2024.04.010
IF: 12.822
2024-04-14
Journal of Advanced Research
Abstract:Highlights • In this study, all investigation and experiments have obtained patients' consent and been approved by the Ethic Committee for Clinical Research of Shanghai Tenth People's Hospital. • Urolithin A inhibits breast cancer cell and tumor macrophage IL-6 secretion through different mechanisms. • Urolithin A suppresses tumor macrophages harmful Inflammation through activation of mitophagy. • Urolithin A-mediated mitophagy and antitumor activity depend on TFEB nuclear translocation. • C212S mutation abolishes the effect of urolithin A blocking 1433 recognition of phosphorylated TFEB. Introduction Urolithin A (UA) is a naturally occurring compound that is converted from ellagitannin-like precursors in pomegranates and nuts by intestinal flora. Previous studies have found that UA exerts tumor-suppressive effects through antitumor cell proliferation and promotion of memory T-cell expansion, but its role in tumor-associated macrophages remains unknown. Objectives Our study aims to reveal how UA affects tumor macrophages and tumor cells to inhibit breast cancer progression. Methods Observe the effect of UA treatment on breast cancer progression though in vivo and in vitro experiments. Western blot and PCR assays were performed to discover that UA affects tumor macrophage autophagy and inflammation. Co-ip and Molecular docking were used to explore specific molecular mechanisms. Results We observed that UA treatment could simultaneously inhibit harmful inflammatory factors, especially for InterleuKin-6 (IL-6) and tumor necrosis factor α (TNF-α), in both breast cancer cells and tumor-associated macrophages, thereby improving the tumor microenvironment and delaying tumor progression. Mechanistically, UA induced the key regulator of autophagy, transcription factor EB (TFEB), into the nucleus in a partially mTOR-dependent manner and inhibited the ubiquitination degradation of TFEB, which facilitated the clearance of damaged mitochondria via the mitophagy-lysosomal pathway in macrophages under tumor supernatant stress, and reduced the deleterious inflammatory factors induced by the release of nucleic acid from damaged mitochondria. Molecular docking and experimental studies suggest that UA block the recognition of TFEB by 1433 and induce TFEB nuclear localization. Notably, UA treatment demonstrated inhibitory effects on tumor progression in multiple breast cancer models. Conclusion Our study elucidated the anti-breast cancer effect of UA from the perspective of tumor-associated macrophages. Specifically, TFEB is a crucial downstream target in macrophages. Graphical abstract Download : Download high-res image (155KB) Download : Download full-size image
multidisciplinary sciences
What problem does this paper attempt to address?